BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

All Posts


What CROs Cite as Their Top …

What CROs Cite as Their Top Clinical Trial Challenges and How They Plan to Overcome Them in 2025

Jan. 10, 2025   by Megan Deegan     --
In a rapidly evolving clinical research landscape, there is a greater need now more than ever for pharma and biotech …
Continue ›››
Discovery of Novel Longevity Therapeutics that …

Discovery of Novel Longevity Therapeutics that Target Mitochondrial Enzymes

Jan. 9, 2025   by Illia Petrov     News
Researchers at CCM Biosciences, a New Jersey-based biopharmaceutical company, have reported the discovery of first-in-class compounds designed to restore the …
Continue ›››
Merck KGaA Adopts Quris-AI’s Organ-On-Chip Platform …

Merck KGaA Adopts Quris-AI’s Organ-On-Chip Platform for Preclinical Drug Safety Testing

Jan. 9, 2025   by Andrii Buvailo, PhD     News
Merck KGaA has integrated Quris-AI’s Bio-AI platform into its drug development pipeline to evaluate small molecule drug candidates for safety …
Continue ›››
PostEra and Pfizer Expand $610M Partnership …

PostEra and Pfizer Expand $610M Partnership for AI-Driven ADC Development

Jan. 8, 2025   by Roman Kasianov     News
PostEra, Boston biotech specializing in AI-driven drug discovery, announced an expansion of its collaboration with Pfizer, increasing the total partnership …
Continue ›››
Tempus and Genialis Partner on RNA-Based …

Tempus and Genialis Partner on RNA-Based Biomarker Algorithms

Jan. 8, 2025   by BiopharmaTrend      News
Tempus AI has partnered with Genialis to develop RNA-based biomarker algorithms aimed at improving cancer diagnostics and treatment outcomes. This …
Continue ›››
Novo Nordisk and Valo Health Expand …

Novo Nordisk and Valo Health Expand AI Collaboration for Cardiometabolic Drug Discovery

Jan. 8, 2025   by Roman Kasianov     News
Novo Nordisk has deepened its partnership with Valo Health, increasing the scope of their collaboration to include up to 20 …
Continue ›››
Recursion Advances Two Investigational Oncology Drugs …

Recursion Advances Two Investigational Oncology Drugs to Clinical Trials

Jan. 7, 2025   by Roman Kasianov     News
Recursion Pharmaceuticals announced the progression of two investigational oncology drugs, REC-3565 and REC-4539, into clinical trials, targeting critical unmet needs …
Continue ›››
Neumora’s Kappa Opioid Antagonist Falters in …

Neumora’s Kappa Opioid Antagonist Falters in Phase 3 Depression Trial

Jan. 7, 2025   by Roman Kasianov     News
Neumora Therapeutics’ lead drug, navacaprant, failed to show efficacy in the Phase 3 "KOASTAL-1" trial for major depressive disorder (MDD), …
Continue ›››
Profluent Unveils AI Model to Advance …

Profluent Unveils AI Model to Advance CRISPR-Cas Systems for Gene Editing

Jan. 7, 2025   by Roman Kasianov     News
Profluent Bio, a Berkeley-based biotech founded in 2022, and funded with $44 million to date, has released an AI model …
Continue ›››
Calico's Small Molecule eIF2B Activator Falls …

Calico's Small Molecule eIF2B Activator Falls Short in ALS Trial

Jan. 7, 2025   by Andrii Buvailo, PhD     News
Calico, the Alphabet-backed biotech focused on aging and longevity, has encountered a hurdle in its efforts to develop treatments for …
Continue ›››
Insilico Medicine Reports Positive Results from …

Insilico Medicine Reports Positive Results from Phase I Trials of ISM5411, an AI-Designed Drug for Inflammatory Bowel Disease

Jan. 6, 2025   by Andrii Buvailo, PhD     News
Insilico Medicine announced favorable outcomes from two Phase I clinical trials of ISM5411, a gut-restricted PHD1/2 inhibitor designed for inflammatory …
Continue ›››
Orbis Medicines Raises €90 Million For …

Orbis Medicines Raises €90 Million For Oral Macrocycles, Backed by Novo Holdings and Eli Lilly

Jan. 6, 2025   by BiopharmaTrend     News
Denmark-based Orbis Medicines has raised €90 million ($93.2 million) in a Series A financing round to advance its development of …
Continue ›››
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.